EXENDIN-4
Intervention1 paper1 findingPubChem 56927919ChEBI 64073
- Human trial1
Outcomes
1CD14+OCN+ monocytes
no changein human cells1−8.5%Very low certainty
1 study
CD14+OCN+ monocytes
no changein human cells1−8.5%Very low certainty
EXENDIN-4 has no effect on CD14+OCN+ monocytes in human cells (-8.5%).
Cells24 hn = 10
Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study · Acta diabetologica · 21 Sep 2026
Trials
6In trials
Phase 4 · Results posted · 2 trials
Phase 3 · Completed · 2 trials
Phase 2 · Terminated · 1 trial
Phase 2 · Terminated · 1 trial
Phase 2 · Status unknown · 1 trial
Stopped
NCT01255163 · Terminated · Alzheimer's disease
AstraZeneca withdrew support for the study.
Trial sponsors
Company1 trialPhase 3456 people
1 trialPhase 476 people
Carl T. Hayden VA Medical Center
1 trialPhase 476 people
Centre Hospitalier Universitaire de Besancon
2 trialsPhase 2/3174 people
1 trialPhase 257 people
University College London (UCL) Cancer Institute
1 trialPhase 240 people